COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00277381
Recruitment Status : Completed
First Posted : January 16, 2006
Last Update Posted : March 1, 2013
Information provided by (Responsible Party):
Joseph C. Kvedar, Massachusetts General Hospital

Brief Summary:
Treating hypertension is known to decrease morbidity and mortality. Despite this 70% of patients do not have adequately controlled blood pressure. The main reason for this is non-adherence to recommended drug therapy. Although strategies have been developed to improve adherence many are time consuming and expensive. We propose to use communications technology to develop a novel means of improving adherence to antihypertensive therapy. We will conduct a randomised, single-blinded, controlled study to assess the impact of a real-time, automated reminder system on adherence rates. This will involve adapting two pieces of currently available technology - the electronic pill bottle and the Ambient Globe. The Globe will change colour in response to information received, via a wireless link, from the patient's electronic pill bottle. We hypothesise that this will provide patients with an up to date, but unobtrusive, reminder of their adherence status and thus effect positive behavioural change. We will measure the impact of this intervention on adherence rates as well as assessing patient views and the impact on provider workload. This trial will elucidate the role of communications technology in improving adherence behaviour and allow us to develop further strategies to tackle this major health issue.

Condition or disease Intervention/treatment Phase
Hypertension Behavioral: Automated feedback regarding drug adherence Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Official Title: Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology
Study Start Date : July 2006
Actual Primary Completion Date : January 2008
Actual Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Adherence rates as measured using data held in the SIMpill database
  2. Patient satisfaction with intervention as assessed by questionnaire at the end of the study.
  3. Technical difficulties as assessed by interview at the end of the study and by review of the technical log.

Secondary Outcome Measures :
  1. Discontinuation rates of medication as assessed at the end of trial debrief.
  2. Changes to medication regime as assessed at the end of trial debrief.
  3. Adverse events (e.g. hospitalisation) as assessed from the log of withdrawals from the trial.
  4. Blood pressure as measured on enrollment and at end of trial debrief.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Prescription of a once-a-day dose of atenolol.
  • Morisky Score of less than or equal to 2 (explanation in 'Equitable Selection of Subjects').
  • Fluency in English.
  • Age 45-65 inclusive.
  • Primary Care Physician consent to the patient taking part.

Exclusion Criteria:

  • Patients prescribed more than two anti-hypertensive agents.
  • Patients prescribed more than four medications in total.
  • Patients on secondary prevention following cardiac event or stroke.
  • Morisky Score of more than 2.
  • Patients with visual impairment or color-blindness.
  • Patients with congenital or acquired cognitive impairment.
  • Patients with a cardiac pacemaker

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00277381

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Layout table for investigator information
Principal Investigator: Joseph C. Kvedar, MD Partners Healthcare System
Layout table for additonal information
Responsible Party: Joseph C. Kvedar, Director, Center for Connected Health, Massachusetts General Hospital Identifier: NCT00277381    
Other Study ID Numbers: 2005-P-002248
First Posted: January 16, 2006    Key Record Dates
Last Update Posted: March 1, 2013
Last Verified: February 2013
Keywords provided by Joseph C. Kvedar, Massachusetts General Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases